Literature DB >> 2938594

Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction.

A Murai, T Miyahara, N Fujimoto, M Matsuda, M Kameyama.   

Abstract

Attempts were made to prepare antisera monospecific for Lp(a) lipoprotein and to investigate the distribution of subjects according to plasma levels of Lp(a) in Japanese controls and patients with coronary heart disease or cerebral infarction. Positive plasma reactions to the double diffusion test for Lp(a) (Ouchterlony) were observed in 32.3% of the healthy Japanese subjects, which is similar to results previously reported in western countries. The plasma threshold level of 17 mg/dl was considered an appropriate point for dividing subjects into positive and negative groups depending on reactions to the double diffusion test. When subjects were divided into two groups at 17 mg/dl, a significant association was found between a high plasma level of Lp(a) and either coronary heart disease or cerebral infarction in the distribution of the cortical artery. These results suggest that Lp(a) may play an important part as a risk factor for coronary heart disease and cerebral infarction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938594     DOI: 10.1016/0021-9150(86)90048-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  33 in total

Review 1.  The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.

Authors:  C Sarti; M Kaarisalo; J Tuomilehto
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  Ischemic Stroke Prevention.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

3.  Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery.

Authors:  J S Skinner; M Farrer; C J Albers; K Piper; H A Neil; P C Adams
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

4.  Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.

Authors:  J M Edelberg; M Weissler; S V Pizzo
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

5.  Expressed hypervariable polymorphism of apolipoprotein (a).

Authors:  M I Kamboh; R E Ferrell; B A Kottke
Journal:  Am J Hum Genet       Date:  1991-11       Impact factor: 11.025

Review 6.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

7.  Like father like son? Sons of patients of European or Indian origin with coronary artery disease reflect their parents' risk factor patterns.

Authors:  N Shaukat; D P de Bono; D R Jones
Journal:  Br Heart J       Date:  1995-09

8.  Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.

Authors:  S Takahashi; T Yamamoto; Y Moriwaki; Z Tsutsumi; K Higashino
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

9.  Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease.

Authors:  C Sandholzer; E Boerwinkle; N Saha; M C Tong; G Utermann
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

10.  Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.

Authors:  M Farrer; F L Game; C J Albers; H A Neil; P H Winocour; M F Laker; P C Adams; K G Alberti
Journal:  BMJ       Date:  1993-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.